Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.62 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.61 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.58 |
| ▸ | PPARG | P37231 | 7/20 | 0.58 |
| ▸ | PPARD | Q03181 | 7/20 | 0.58 |
| ▸ | PPARA | Q07869 | 7/20 | 0.58 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.58 |
| ▸ | TSHR | P16473 | 4/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | TLR2 | O60603 | 2/20 | 0.58 |
| ▸ | FABP4 | P15090 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Heptane SCHEMBL3485862 | 0.98 | GPR84 (0.62) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL2818571 | 0.98 | FFAR3 (0.59) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL834319 | 0.93 | FFAR3 (0.72) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Hexanoate SCHEMBL3411666 | 0.91 | AKR1B1 (0.76) | AKR1B1GPR84PPARGPPARDPPARA | |
| Butyric Acid SCHEMBL5477656 | 0.90 | FFAR3 (0.68) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Butyric Acid SCHEMBL8517702 | 0.90 | FFAR3 (0.68) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Heptanoate SCHEMBL3410001 | 0.88 | GPR84 (0.77) | AKR1B1GPR84PPARGPPARDPPARA | |
| Decanoic Acid SCHEMBL5875269 | 0.88 | GPR84 (0.77) | AKR1B1GPR84PPARGPPARDPPARA | |
| Octanoic Acid SCHEMBL3414554 | 0.88 | GPR84 (0.77) | AKR1B1GPR84PPARGPPARDPPARA | |
| Undecanoate SCHEMBL21145218 | 0.88 | GPR84 (0.77) | AKR1B1GPR84PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11931431-B2 | PSMA-targeted radiopharmaceutical for diagnosing and treating prostate cancer | FUTURECHEM CO., LTD (KR) | 2024-03-19 | — | — | US | disclosed |
| EP-3778592-B1 | PSMA-TARGETED RADIOPHARMACEUTICAL FOR DIAGNOSING AND TREATING PROSTATE CANCER | FUTURECHEM CO LTD (KR) | 2023-04-26 | — | — | EP | disclosed |
| US-20210106701-A1 | PSMA-TARGETED RADIOPHARMACEUTICAL FOR DIAGNOSING AND TREATING PROSTATE CANCER | FUTURECHEM CO., LTD (KR) | 2021-04-15 | — | — | US | disclosed |
| EP-3778592-A1 | PSMA-TARGETED RADIOPHARMACEUTICAL FOR DIAGNOSING AND TREATING PROSTATE CANCER | Futurechem Co., Ltd. (KR) | 2021-02-17 | — | — | EP | disclosed |
| EP-3604533-A1 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | Arbutus Biopharma Corporation (CA) | 2020-02-05 | — | — | EP | disclosed |
| CN-106029675-B | Pyridyl group diamino transition metal complex, its preparation and use | 埃克森美孚化学专利公司 | 2019-11-19 | — | — | CN | disclosed |
| CN-109563110-A | Quinolyl diamino transition metal complex, production and purposes | 埃克森美孚化学专利公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-104995196-B | Biotin variants, streptavidin mutants and uses thereof | 赛威德医疗公司 | 2018-10-12 | — | — | CN | disclosed |
| US-20180221494-A1 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-08-09 | — | — | US | disclosed |
| US-20180066009-A1 | Nucleosides and Oligonucleotides for Studies on Reversal of Cytotoxic and Mutagenic Damage of DNA and as Diagnostics Tools | CHEMGENES CORP (US) | 2018-03-08 | — | — | US | disclosed |
| US-5091533-A | Treating allergies, cardiovascular disorders, inflammation | MERCK FROSST CANADA, INC. (CA) | 1992-02-25 | — | — | US | disclosed |
| EP-0447189-A1 | 5-Hydroxy-2,3-dihydrobenzofuran analogs as leukotriene biosynthesis inhibitors | MERCK FROSST CANADA INC. (CA) | 1991-09-18 | — | — | EP | disclosed |
| EP-0422889-A2 | Phenethanolamine compounds | GLAXO GROUP LIMITED (GB) | 1991-04-17 | — | — | EP | disclosed |
| EP-0367576-A2 | Estrogen nucleus derivatives for use in the inhibition of sex steroid activity | ENDORECHERCHE INC. (CA) | 1990-05-09 | — | — | EP | disclosed |
| EP-0227472-B1 | 10 BETA-ALKYNYLESTRENE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | FARMITALIA CARLO ERBA S.r.l. (IT) | 1989-10-18 | — | — | EP | disclosed |
| EP-0311010-A2 | Alpha,Alpha-disubstituted aromatics and heteroaromatics as cognition enhancers | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1989-04-12 | — | — | EP | disclosed |
| US-4808578-A | ANTICARCINOGENIC AGENTS | FARMITALIA CARLO ERBA S. R. L. (IT) | 1989-02-28 | — | — | US | disclosed |
| US-4783483-A | Epoxides useful as antiallergic agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-11-08 | — | — | US | disclosed |
| US-4670569-A | 5-fluoro-PGI2 compounds | G. D. SEARLE & CO. (US) | 1987-06-02 | — | — | US | disclosed |
| US-4540801-A | 5 Fluoro PGI compounds | G. D. SEARLE & CO. (US) | 1985-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11931431-B2 | PSMA-targeted radiopharmaceutical for diagnosing and treating prostate cancer | FOLH1, PSMA1, KLK3 | FFAR3 2731/4885HDAC3 1762/4885HDAC1 982/4885 |
| US-20180221494-A1 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | HAVCR2, LNPEP, BST2 | FFAR3 3932/4885HDAC3 3547/4885HDAC1 4388/4885 |
| US-20210106701-A1 | PSMA-TARGETED RADIOPHARMACEUTICAL FOR DIAGNOSING AND TREATING PROSTATE CANCER | FOLH1, PSMA1, KLK3 | FFAR3 2731/4885HDAC3 1762/4885HDAC1 982/4885 |
| US-20180066009-A1 | Nucleosides and Oligonucleotides for Studies on Reversal of Cytotoxic and Mutagenic Damage of DNA and as Diagnostics Tools | UNG, OGG1, ADAR | FFAR3 2932/4885HDAC3 4314/4885HDAC1 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.